Clinical Trial

Efficacy of Bioactive Glass vs. Xenograft in Maxillary Sinus Augmentation

Study acronym: BIOXENO
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This randomized controlled study aims to evaluate the clinical, radiographic, and histologic efficacy of using bioactive glass bone graft (UNIGRAFT by Biomed Inc., USA) compared to a conventional xenograft in maxillary sinus augmentation procedures. A total of 20 patients classified as SA4 according to the Misch classification will be enrolled and randomly allocated into two groups. Outcomes will be assessed using Cone Beam Computed Tomography (CBCT) for vertical bone gain and, where applicable, histologic analysis. The study is conducted at the Faculty of Dentistry, Suez Canal University.
Trial Details
NCT Number NCT07125846
Lead Sponsor Suez Canal University
Conditions Alveolar Bone Loss, Maxillary Sinus Disease, Tooth Loss
Enrollment 20 participants
Start Date 2025-10-15
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-15